Journal Articles Cancer Chemotherapy and Pharmacology Year : 2022

Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer

Fabrice Barlesi
Elissa Cousin
  • Function : Author
  • PersonId : 966865
  • IdRef : 201760436
Mathieu Barbolosi
  • Function : Author
Pascale Tomasini
  • Function : Author
Melissa Galloux
  • Function : Author
Albane Testot-Ferry
  • Function : Author
Annick Pelletier
  • Function : Author
Nicolas André

Abstract

A phase Ia/Ib trial of metronomic oral vinorelbine (MOV) driven by a mathematical model was performed in heavily pretreated metastatic Non-Small Cell Lung Cancer or Pleural Mesothelioma patients. Disease Control Rate, progression free survival, toxicity and PK/PD were the main endpoints.
No file

Dates and versions

hal-03923667 , version 1 (04-01-2023)

Identifiers

Cite

Fabrice Barlesi, Laure Deyme, Diane-Charlotte Imbs, Elissa Cousin, Mathieu Barbolosi, et al.. Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer. Cancer Chemotherapy and Pharmacology, 2022, 90 (2), pp.149-160. ⟨10.1007/s00280-022-04455-x⟩. ⟨hal-03923667⟩
47 View
0 Download

Altmetric

Share

More